Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

SHR Neuro Cancer Cardio Metab Microb Lipid

SAFE: Special Non-Invasive Advances in Foetal and Neonatal Evaluation Network

Abstract: The establishment of non-invasive markers for prenatal diagnosis and neo-natal screening is a very important research goal. Current invasive procedures have (1)a significant risk of induced abortion (1-2%) or maternal injury and (2) considerable discomfort and psycological distress. Currently around 5 % of pregnant women in the developed world undergo invasive prenatal diagnosis procedures, mainly due to an increased risk for foetal chromosome abnormalities(such as trisomy 21 Down syndrome). In populations with a high penetrance of an inherited genetic disorder, such as the hemoglobinopathies, cystic fibrosis or Tay Sachs syndrome, it may be advantageous to determine the genotype early in life (neonates), as this will alert individuals, who are found o be carriers of the risk of having an affected child.
The transplacental passage of foetal cells into the maternal circulation is now well established, and a number of studies have been undertaken in order to isolate these rare foetal cells for prenatal diagnostic purposes. In spite of the technical problems imposed by the scarcity of these foetal cells, substantial progress has been made by individual research groups in Europe. There is now an urgent need to integrate these fragmented and diverse activities into a coherent strategy for non-invasive prenatal diagnosis.
The recent discovery of relatively abundant quantities of cell free DNA in maternal plasma and serum has opened a new avenue for the prenatal diagnosis of the latter group of genetic disorders as well as the determination of the foetal RhD genotype in pregnancies at risk for HDN (haemolytic disease of the foetus and newborn). In addition elevations in the concentration of the new found molecular analyte may be indicative of pregnancies bearing an aneuploid foetus or those at risk for pregnancy related disorders such as preterm labour or preeclampsia. This opens the possibility for new screening tools.
The advent of high throughput gene-CHIP technology will facilitate effective screening programs for common inherited genetic disorders. Thir will alert individuals to the possibility of having an affected foetus if the partner has a certain genetic constellation; a frequent dispensation in certain populations. The program will create a leading European Network of Excellence in the area of non-invasive prenatal diagnosis and neonatal screening.

Local Subprojectlead:: Sedlmayr Peter

Duration:: 01.03.2004-28.02.2009

Programme:: EU (FP-6)

EU-Project Instruments: Network of Excellence (NoE)

Type of Research: applied research

Staff: Sedlmayr, Peter, Project Leader

MUG Research Units: Department of Obstetrics and Gynaecology; Division of Cell Biology, Histology and Embryology

Project partners: All India Institute of Medical Sciences, India
Contact person: Madhulika Kabra;; Alma Mater Studiorum-Universita di Bologna Dipartimento di Medicina Interna Cardioangiologia Epatologia, Italy
Contact person: Giovanni Romeo;; American Hospital of Paris, France
Contact person: Jean-Marc Costa;; Charles University Prague, 2nd Medical Faculty, Czech Republic
Contact person: Iliona Hromadnikova;; Danek Gertner Institute of human genetics sheba medical center, Israel
Contact person: Esther Guetta;; Department of Clinical Chemistry/University Medical Center Nijmegen , Netherlands
Contact person: Dorine Swinkels;; Dept. of Medical Genetics/Athens University School of Medicine , Greece
Contact person: Ariadni Mavrou;; Dipartimento di Scienza della Cognizione e della Formazione/Università degli Studi di Trenti (DISCOF) , Italy
Contact person: Lucia Savadori;; Ecole Pratique des Hautes Etudes, France
Contact person: Etienne Mullet;; Estonian Biocentre (EBC), Estonia
Contact person: Anderas Metspalu;; Fondazione Centro San Raffaele del Monte Tabor (FCSR), Italy
Contact person: Laura Cremonesi;; Georg-August-University Goettingen/Bereich Humanmedizin , Germany
Contact person: Tobias J. Legler;; Helsinki University, Finland
Contact person: Jim Schröder;; Hospital Universitario Central de Asturias, Spain
Contact person: Francisco Alvarez;; Imperial College London, United Kingdom
Contact person: Nicolas M. Fisk;; IMSTAR SA, France
Contact person: KhuongTruong;; Institut National de Sante et Recherche Medicale, France
Contact person: Patricia Paterlini;; Institute of Genetics and Biophysics "A. Buzzati Traverso", Italy
Contact person: Maurizio D'Esposito;; Karolinska Institut, Sweden
Contact person: Elisabeth Blennow;; KELLANTIS S.A.R.L, France
Contact person: Philippe Cornet;; King's College London, United Kingdom
Contact person: Theresa Marteau;; Leon Kozminski Academy of Entrepreneurship and Management, Poland
Contact person: Tadeusz Tyszka;; Lund University Hospital Blood Centre, Sweden
Contact person: Martin Olsson;; Meta Systems GmbH, Germany
Contact person: Andreas Plesch;; Microbiology Research Centre Holland, Netherlands
Contact person: Jan Schouten;; National Blood Authority, United Kingdom
Contact person: Geoff Daniels;; Oxford Brookes University, United Kingdom
Contact person: William Clocksin;; PALM Microlaser Technologies AG, Germany
Contact person: Renate Burgemeister;; Rigshospitalet University of Copenhagen, Denmark
Contact person: John Philip;; Sanquin Blood Supply Foundation, Netherlands
Contact person: Ellen van der Schoot;; Statens Serum Institut, Denmark
Contact person: Michael Christiansen;; Statistik Dr. M. Buser, Switzerland
Contact person: Mauro Buser;; The Cyprus Institute of Neurology and Genetics, Cyprus
Contact person: Marina Kleanthous and Phillipos C. Patsalis;; The Genetic interest group, United Kingdom
Contact person: Alastair Kent;; The open University Centre for education in Medicine, United Kingdom
Contact person: Janet Grant;; The Rare Chromosome Disorder Support group, United Kingdom
Contact person: Prisca Middlemiss;; Universitat Rovira i Virgili, Spain
Contact person: Ciara O'Sullivan;; University College, London, United Kingdom
Contact person: Lyn Chitty and Charles Rodeck;; University Court of the University of Aberdeen (UNIABDN), United Kingdom
Contact person: Stan Urbaniak;; University of Bari, Italy
Contact person: Edoardo Di Naro;; University of Basel, Switzerland
Contact person: Sinuhe Hahn;; University of Bristol, United Kingdom
Contact person: Andres López Bernal and Peter Soothill;; University of Copenhagen, Denmark
Contact person: Lars Larsen;; University of Perugia, Italy
Contact person: Gian Carlo Di Renzo;; University of the West fo England, Bristol, United Kingdom
Contact person: Neil Avent;; University of Trieste: Higher Education in Clinical Engeneering(SIIC-HECE) c/o DEEI, Italy
Contact person: Lucia Savadori;; University of Warwick, United Kingdom
Contact person: Kate Hughes, Simon Bailey;; University of Zurich, Switzerland
Contact person: Michael Siegrist;; Up-to-date Informatik AG, Switzerland
Contact person: Jürg Rohrer;; Zhongshan Medical College/Sun Yat-Sen University , China
Contact person: Yiming Wang;

Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium

Project results published: > Verification of the genomic identity of candidate ... Chimerism. 2011; 2(3):63-64; > Microchimerism. Implications for immunology and pr... Seminar; NOV 29, 2010; Wuxi, CHINA. 2010.; > Single cell analysis for non-invasive prenatal dia... Proceedings of the 1st Central-Eastern European Symposium on Free Nucleic Acids in Non-Invasive Prenatal Diagnosis. 2010; 22-28.-1st Central-Eastern European Symposium on Free Nucleic Acids in Non-Invasive Prenatal Diagnosis; MARCH 19, 2010; Budapest, HUNGARY. (ISBN: 978-963-9129-73-3 ); > Microchimerism: implications for immunology and pr... AMER J REPROD IMMUNOL. 2010; 64: 6-6.-. 2nd International Conference on Reproductive Immunology; NOV 28 - DEC 2, 2010; Shanghai. CHINA.